Credit Suisse analyst Judah Frommer raised the firm’s price target on Sarepta to $137 from $114 and keeps a Neutral rating on the shares. With SRP-9001’s May 29th PDUFA date approaching, the firm is reviewing anticipated regulatory milestones likely to move Sarepta stock in the coming weeks/months. While accelerated approval of ‘9001 is Credit Suisse’s base case, the firm sees near-term sources of potential volatility.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SRPT:
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- UBS Says These 2 Stocks Offer Attractive Risk-Reward Right Now — Here’s Why
- Sarepta price target raised to $125 from $114 at Cowen
- Sarepta price target raised to $160 from $158 at Needham
- Sarepta price target raised to $114 from $101 at Credit Suisse
